BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

492 related articles for article (PubMed ID: 29961332)

  • 1. Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation.
    Sun B; Jia Y; Hong J; Sun Q; Gao S; Hu Y; Zhao N; Zhao R
    J Agric Food Chem; 2018 Jul; 66(29):7633-7642. PubMed ID: 29961332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of hepatic peroxisome proliferator-activated receptor α/γ in the therapeutic effect of osthole on high-fat and high-sucrose-induced steatohepatitis in rats.
    Zhao X; Xue J; Wang XL; Zhang Y; Deng M; Xie ML
    Int Immunopharmacol; 2014 Sep; 22(1):176-81. PubMed ID: 24993341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Betaine prevented fructose-induced NAFLD by regulating LXRα/PPARα pathway and alleviating ER stress in rats.
    Ge CX; Yu R; Xu MX; Li PQ; Fan CY; Li JM; Kong LD
    Eur J Pharmacol; 2016 Jan; 770():154-64. PubMed ID: 26593707
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sesamin ameliorates hepatic steatosis and inflammation in rats on a high-fat diet via LXRα and PPARα.
    Zhang R; Yu Y; Hu S; Zhang J; Yang H; Han B; Cheng Y; Luo X
    Nutr Res; 2016 Sep; 36(9):1022-1030. PubMed ID: 27632923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PARP1-mediated PPARα poly(ADP-ribosyl)ation suppresses fatty acid oxidation in non-alcoholic fatty liver disease.
    Huang K; Du M; Tan X; Yang L; Li X; Jiang Y; Wang C; Zhang F; Zhu F; Cheng M; Yang Q; Yu L; Wang L; Huang D; Huang K
    J Hepatol; 2017 May; 66(5):962-977. PubMed ID: 27979751
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Li-Gan-Shi-Liu-Ba-Wei-San improves non-alcoholic fatty liver disease through enhancing lipid oxidation and alleviating oxidation stress.
    Jiang Y; Chen L; Wang H; Narisi B; Chen B
    J Ethnopharmacol; 2015 Dec; 176():499-507. PubMed ID: 26571089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARα/γ agonists and antagonists differently affect hepatic lipid metabolism, oxidative stress and inflammatory cytokine production in steatohepatitic rats.
    Zhang Y; Cui Y; Wang XL; Shang X; Qi ZG; Xue J; Zhao X; Deng M; Xie ML
    Cytokine; 2015 Sep; 75(1):127-35. PubMed ID: 26194065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium butyrate protects against high-fat diet-induced oxidative stress in rat liver by promoting expression of nuclear factor E2-related factor 2.
    Sun B; Jia Y; Yang S; Zhao N; Hu Y; Hong J; Gao S; Zhao R
    Br J Nutr; 2019 Aug; 122(4):400-410. PubMed ID: 31204637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oxymatrine attenuates hepatic steatosis in non-alcoholic fatty liver disease rats fed with high fructose diet through inhibition of sterol regulatory element binding transcription factor 1 (Srebf1) and activation of peroxisome proliferator activated receptor alpha (Pparα).
    Shi LJ; Shi L; Song GY; Zhang HF; Hu ZJ; Wang C; Zhang DH
    Eur J Pharmacol; 2013 Aug; 714(1-3):89-95. PubMed ID: 23791610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ascorbic acid inhibits visceral obesity and nonalcoholic fatty liver disease by activating peroxisome proliferator-activated receptor α in high-fat-diet-fed C57BL/6J mice.
    Lee H; Ahn J; Shin SS; Yoon M
    Int J Obes (Lond); 2019 Aug; 43(8):1620-1630. PubMed ID: 30283077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular adaptations underlying the beneficial effects of hydroxytyrosol in the pathogenic alterations induced by a high-fat diet in mouse liver: PPAR-α and Nrf2 activation, and NF-κB down-regulation.
    Valenzuela R; Illesca P; Echeverría F; Espinosa A; Rincón-Cervera MÁ; Ortiz M; Hernandez-Rodas MC; Valenzuela A; Videla LA
    Food Funct; 2017 Apr; 8(4):1526-1537. PubMed ID: 28386616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protective effect and mechanism of Qiwei Tiexie capsule on 3T3-L1 adipocytes cells and rats with nonalcoholic fatty liver disease by regulating LXRα, PPARγ, and NF-κB-iNOS-NO signaling pathways.
    Suolang PC; Liu BQ; Chen J; De J; Nima ZB; Dunzhu CR
    J Ethnopharmacol; 2019 May; 236():316-325. PubMed ID: 30851372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of herbal composition Gambigyeongsinhwan (4) on hepatic steatosis and inflammation in Otsuka Long-Evans Tokushima fatty rats and HepG2 cells.
    Yoon S; Kim J; Lee H; Lee H; Lim J; Yang H; Shin SS; Yoon M
    J Ethnopharmacol; 2017 Jan; 195():204-213. PubMed ID: 27845265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation.
    Wu X; Zheng H; Yang R; Luan X; Zhang L; Jin Q; Jin Y; Xue J
    Am J Physiol Endocrinol Metab; 2019 Sep; 317(3):E436-E445. PubMed ID: 31211621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beneficial effects of neomangiferin on high fat diet-induced nonalcoholic fatty liver disease in rats.
    Zhou C; Zhou J; Han N; Liu Z; Xiao B; Yin J
    Int Immunopharmacol; 2015 Mar; 25(1):218-28. PubMed ID: 25661699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
    Liu H; Zhong H; Yin Y; Jiang Z
    Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ginsenoside Rg1 Protects against Non-alcoholic Fatty Liver Disease by Ameliorating Lipid Peroxidation, Endoplasmic Reticulum Stress, and Inflammasome Activation.
    Xu Y; Yang C; Zhang S; Li J; Xiao Q; Huang W
    Biol Pharm Bull; 2018 Nov; 41(11):1638-1644. PubMed ID: 30135326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Farnesol induces fatty acid oxidation and decreases triglyceride accumulation in steatotic HepaRG cells.
    Pant A; Rondini EA; Kocarek TA
    Toxicol Appl Pharmacol; 2019 Feb; 365():61-70. PubMed ID: 30611723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.